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Abstract
Purpose—Pre-exposure prophylaxis (PrEP) is an effective and safe intervention to prevent HIV 
transmission in men who have sex with men; current CDC guidelines indicate its use among high-
risk adults. Adolescent sexual minority males (ASMM) also have significant HIV risk, but 
implementation strategies are likely to differ for this population. We aimed to estimate impact and 
efficiency of PrEP for ASMM in higher-prevalence US settings, using a variety of implementation 
strategies and assumptions about coverage, adherence, and background prevalence.
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Methods—We develop a stochastic, dynamic, network-based model, parametrized using 
numerous ASMM behavioral and clinical data sources. We simulate 10 years with and without 
PrEP, comparing percent of incident infections averted (impact) and number of person-years on 
PrEP per infection averted (efficiency).
Results—Our main scenario (PrEP for 16–18 year-old ASMM, initiating PrEP six months after 
first anal intercourse, 40% coverage, adherence profiles from the ATN 113 trial; 2.9% background 
HIV prevalence among ASMM) prevents 27.8% of infections, with 38 person-years on PrEP per 
infection averted. Expanding implementation to cover younger ages or earlier initiation has small 
effects on impact and efficiency. Targeting highest-risk ASMM increases efficiency, but requires 
querying sexual histories. Across levels examined, coverage and adherence do not have major 
impacts on efficiency, while background prevalence does.
Conclusions—PrEP can have a large impact on HIV incidence among ASMM in the United 
States, especially in settings with high prevalence. However, willingness of, and support for, 
providers will be central to achieving the coverage needed to make this a success.
Keywords
Adolescent sexual minority males; homosexual males; bisexual males; HIV; pre-exposure 
prophylaxis; mathematical modeling
IMPLICATIONS AND CONTRIBUTION
This study uses modeling and recent trial data to estimate impact and efficiency for HIV pre-
exposure prophylaxis (PrEP) among adolescent sexual minority males in higher-prevalence 
US settings under different targeting strategies. We find that PrEP can have a large impact on 
HIV incidence in this population, with reasonable efficiency.
Pre-exposure prophylaxis (PrEP) with daily oral combined tenofovir/emtricitabine is an 
effective and safe intervention to prevent human immunodeficiency virus (HIV) infection in 
adult men who have sex with men (MSM)(1, 2). Current CDC guidelines indicate use for 
sexually-active adult MSM at substantial risk for HIV acquisition, based on recent patterns 
of anal sex, monogamy, condom use, partner HIV status, and STI diagnosis, or who have 
injected drugs and shared needles (3). PrEP initiation requires a prescription; current CDC 
guidelines for ongoing PrEP users promote quarterly HIV tests, 6-monthly sexually 
transmitted infection (STI) tests, and screening for various side effects at both intervals.
Adolescent sexual minority males (ASMM)—ie, males under 18 who identify as gay or 
bisexual, or are sexually active with other males—have significant HIV risk. For instance, 
sexually-debuted high-school ASMM report higher frequencies of multiple risk behaviors 
than do sexually-debuted high-school adolescent males with only female partners, including 
prevalence of 4+ lifetime partners (33.4% vs. 25.4%), condomless last sex (48.6% vs. 
37.9%), and use of drugs/alcohol at last sex (32.2% vs. 24.1%) (4). Although surveillance-
based HIV incidence measures are not available for ASMM (5), measures of new diagnoses 
illuminate the high HIV risk that ASMM experience nationally. The Centers for Disease 
Control and Prevention (CDC) estimated that in 2015, 13–24-year-old adolescents and 
young adults comprised 22% of all new US HIV diagnoses, and 81% of the adolescent/
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young adult diagnoses were in ASMM, for a total of 7,159 of 39,920 diagnoses (6). 
Nineteen percent of ASMM diagnoses occurred by age 19 and it remains unknown what 
proportion of all ASMM diagnoses reflect infections that occurred before 18. Per total 
population-based rates for 13–24-year-old MSM illustrate this group to have consistently the 
second-highest diagnosis rates among MSM, but stable diagnosis rates since 2010 (7). In the 
absence of surveillance-based incidence estimates and ASMM-specific denominators for 
estimating most-relevant rates (8), research studies have provided critical insights into the 
HIV burden among ASMM. HIV incidence among 16–17-year-old Chicago ASMM has 
been estimated at 5.2/100 person-years, and prevalence among 16–20-year-olds at 7.6% (9). 
Studies of adult MSM find HIV in the youngest participants, implying substantial risk in 
adolescents; e.g., HIV prevalence estimates among 18–22 year-old MSM from three rounds 
of the National HIV Behavioral Surveillance system were 11–14% (10). The InvolveMENt 
cohort (Atlanta) estimated 7.0% HIV prevalence among 18–19 year-olds (11), and the P18 
cohort (New York City) reported HIV incidence of 2.9/100 person-years in MSM of the 
same ages (12). These population-specific estimates of HIV incidence are over 200-fold 
those seen in the general US population (5).
Initial PrEP trials and demonstration projects for MSM included only adults aged 18+ (1, 2, 
13). Given the lack of adolescent-specific efficacy and safety data, current FDA indications 
only include adults, and CDC’s clinical practice guidelines currently recommend that the 
risks and benefits of PrEP for adolescents be weighed carefully “in the context of local laws 
and regulations about autonomy in health care decision-making by minors” (3). One safety 
and feasibility study of PrEP in ASMM in the US aged 15–17 (ATN 113) was recently 
completed. Averaged across measured time points, high adherence (≥4 doses/week) in ATN 
113 (41.6%) was lower than in a recent demonstration project with adult MSM (61.9%) (13–
15). ATN 113 showed a high incidence rate (6.41 infections/100 person-years), higher than 
the 3.29 infections/100 person-years observed in its 18–22 year old MSM counterpart ATN 
110 (16), although all infections in ATN 113 were among those whose drug levels indicated 
poor-to-no adherence. These results highlight the need for targeted research in adolescents to 
understand the impact PrEP may have on HIV incidence, and the unique challenges for 
ASMM in uptake, adherence, and defining and accessing target populations. Since risk 
behaviors evolve rapidly during adolescence, this could be a uniquely valuable time to get 
ASMM on PrEP surrounding specific high-risk behaviors, establishing early a norm of 
sexual health protection.
A broad definition of ASMM includes adolescents who either identify as gay/bisexual or 
have a history of sex with males; one key decision for future PrEP guidelines among 
ASMM, then, is whether to target adolescent populations based on sexual identity or 
reported risk behaviors. Overall impact (ie, cases averted) and efficiency (ie, number needed 
to treat) may depend on targeting strategy and the existing distribution of sexual risk. 
However, methods for identifying ASMM must recognize that they may be in early stages of 
sexual identity formation and may not self-identify as ASMM, nor disclose identity or risk 
behaviors to clinicians or counselors; moreover, not all providers for adolescents are 
prepared to elucidate this information.
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In this study, we developed an agent-based network model of HIV transmission among 
ASMM to inform future guidelines and studies of PrEP interventions in adolescents. We 
modeled an open cohort of 13–18-year-old ASMM, and considered different targeting 
strategies, adherence and coverage levels, and baseline prevalence levels. We estimated the 
impact and efficiency of each strategy, and we interpret these results in the context of each 
strategy’s feasibility within different settings.
METHODS
We developed a stochastic, dynamic model built in the EpiModel software platform 
(www.epimodel.org) based on separable-temporal exponential-family random graph models 
(17). This general statistical model class specifies the probability each pair forms or breaks a 
relationship at each timestep in ways that allow users to preserve arbitrarily complex data-
derived features of network structure. As with our previous adult MSM model (14), we 
modeled relationship formation and dissolution; sexual behavior within relationships (anal 
sex acts, condom use, role selection); HIV testing; HIV treatment initiation, adherence and 
cessation; PrEP initiation and adherence; transmission; intra-host viral dynamics; and agent 
demographic change. We restructured some components, and re-parametrized most, to fit 
ASMM; full details are in the online supplement. Code is available at https://github.com/
statnet/ASMMPrep.
Briefly, males could enter our population at any age 13–18, with entry defined as either 
developing gay or bisexual identity or initiating willingness for sexual activity with another 
male. Those in the latter category immediately became eligible to enter into sexual 
relationships; those in the former had a constant probability of doing so thereafter. Actual 
sexual initiation occurred stochastically some time thereafter. We modeled relationships 
between two ASMM as a function of individual relational propensities and sexual role 
preferences, conditional on both having achieved eligibility. Relational propensities were 
calculated to capture observed variation in partner count, using both explicit (age) and latent 
categories. We included 18-year-olds given programmatic interest in reaching the school-
aged population.
We included an additional constant hazard of infection from MSM above the modeled age 
range. This probability increased with age and varied with individual relational propensity. 
We derived an initial estimate (subsequently altered; see below) for the infection risk per 
week from older MSM for 18-year-olds based on partner age data reported by 19–25 year-
olds (18).
Sexual behavior parameters were drawn from multiple sources (19–21) and new analyses of 
the American Men’s Internet Survey (22), InvolveMENt Study (23), and MAN Project (24), 
with cross-validation when possible. Because this involved only secondary use of existing 
de-identified data sets, it was deemed exempt from review by the University of Washington 
Institutional Review Board. We calibrated our model to 7% HIV prevalence among 18-year-
old ASMM, based on one Atlanta study (11); we then compared resulting incidence 
estimates against others from New York and Chicago (9, 12). We chose the first of these as 
our calibration measure since prevalence is a more stable metric than incidence in the short 
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term, and because some of our behavioral parameters were derived from Atlanta data. We 
varied two inputs—frequency of anal intercourse (AI) within ongoing relationships between 
two ASMM, and weekly probability of HIV infection from non-ASMM partners—for which 
source data were particularly old or subject to desirability bias. Following recent practice in 
epidemic modeling (25), we used approximate Bayesian computation (26) to accept a subset 
of estimates and calculate final parameter values. The final set of parameters that is fixed 
across all scenarios is compiled into two tables in Section 3 of the supplement.
PrEP Scenarios
Our first intervention model (16+/6 mos.; see Table 1) considered PrEP for ASMM aged 16–
18 who had initiated AI, with an average 6-month delay between having indications and 
initiating PrEP, reflecting the average interval expected when sexual debut occurs between 
annual healthcare visits. We considered this a reasonably feasible strategy, as it focused on 
older ASMM, did not require provider elucidation of extensive sexual behavior, and 
included initiation delay. In this, and all modeled scenarios, individuals could terminate 
PrEP while still indicated, given the high discontinuation rate in ATN 113 preliminary data 
(15). We then modeled more expansive strategies allowing for immediate initiation (16+/
immed.), inclusion of younger ASMM (13+/6 mos.), or both (13+/immed.). The 13+/pre-AI 
scenario modeled PrEP initiation occurring prior to AI initiation, when ASMM first begin 
seeking sexual partnerships.
We next considered strategies to focus PrEP among those reporting the greatest risk, 
measured as frequency of condomless AI (CAI) with other ASMM (≥5 or ≥10 CAI acts in 
last 6 months), each for the age groups 16–18 (16+/CAI5 and 16+/CAI10) and 13–18 (13+/
CAI5 and 13+/CAI10). This requires greater provider elucidation of sexual history, but was 
expected to increase intervention efficiency.
For all nine base scenarios, we modeled 40% coverage to match our published adult model: 
at any time, 40% of those meeting relevant criteria were enrolled in PrEP. Our baseline 
cohort adherence profile reflects the means across all measured time points (4–48 weeks) in 
preliminary ATN 113 data (15); 20.9% had no measureable adherence, 24.4% had low 
(corresponding to < 2 pills per week), 13.1% had medium (2–3 pills), and, 41.6% had high 
(4+ pills). Relative risk reduction values for transmission by adherence level were 0%, 31%, 
81%, and 95%, respectively (14, 27). The weighted average of effectiveness across levels 
implies that the average ASMM currently prescribed PrEP would receive a direct 58% 
reduction in per-act acquisition risk. We modeled PrEP termination such that 50% of 
initiators had terminated by 48 weeks (15); these could re-initiate if still indicated.
We conducted sensitivity analyses on coverage and adherence, varying both individually and 
jointly on the 16+/6 mos. scenario. We considered coverage values of 20–60%, and 
optimistic and pessimistic adherence patterns derived from the first and last follow-up visits 
in ATN 113. We conducted a separate sensitivity analysis on background HIV prevalence, 
lowering it by approximately one-half and two-thirds with two scenarios (16+/6 mos. and 
16+/CAI10).
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Simulations and Analysis
Scenarios were conducted on populations of size 10,000 for 10 years. Although no 
individuals remained in the modeled population for this duration, sexual contacts between 
successive cohorts allowed incidence to potentially continue changing over this period. We 
calculated five outcomes for each scenario: HIV incidence; HIV prevalence; the number of 
infections averted (NIA) and percent of infections averted (PIA) relative to no PrEP; and the 
number of person-years on PrEP per infection averted (NNT, number needed to treat). We 
present two prevalence metrics: prevalence among 18-year olds (the metric to which we 
calibrated our model, as described in the Methods, and also an approximation for cumulative 
incidence through age 18 given low adolescent mortality), and across all 13–18 year-old 
ASMM.
Incidence is measured across the final year of the simulation, while NIA and PIA account 
for cumulative incidence across the 10-year time-series. NNT equals person-time on PrEP 
divided by NIA. We present means and 95% credible intervals (CI; middle 95% of simulated 
data) for each outcome across 100 simulations.
RESULTS
Table 2 lists results for all scenarios, and Figure 1 highlights two key metrics (PIA and 
NNT) for our nine main scenarios. Our base scenario (ages 16–18, PrEP initiation 6 months 
after AI initiation, 40% coverage, moderate adherence profile) reduced prevalence among 
18-year-olds from 7.5% to 5.5% (Figure 2a) over 10 years, and prevented 27.8% of 
infections (95% CI 22.3–33.3%). This required 38 person-years on PrEP per infection 
averted. The incidence reduction equilibrated quickly (Figure 2b), beginning at 15% and 
reaching nearly 25% in less than 2 years. This accumulation suggests strong indirect effects 
(ie, secondary cases averted), even when measured across a relatively short portion of the 
lifespan.
Moving PrEP initiation forward to immediately after first AI (16+/immed.) has only a minor 
effect on both PIA and NNT. Reducing the lower limit for indication to age 13 (13+/6 mos., 
13+/immed.) increases PIA more substantially (37.8% for initiation 6 months after AI, 
42.1% for immediate initiation) but at the cost of higher NNT (40 and 41, respectively). 
Enrolling adolescents prior to their first AI experience rather than after had a marginal effect 
on PIA (42.1% to 42.8%).
Scenarios in which PrEP was concentrated among the highest-risk ASMM were all more 
efficient than their more generalized counterparts. For instance, in comparing 16+/immed. to 
16+/CAI10 (ie with ≥10 CAI acts in the last 6 months), PIA declines from 30.1% to 28.1%, 
but NNT also declines (efficiency increases), from 38 to 35. The two scenarios focusing on 
16–18 year-olds with high numbers of recent CAI (5 or 10) achieve the maximum efficiency 
observed. Dropping indication age but continuing to focus on CAI counts increases both PIA 
(to 39.4% and 40.4%) and NNT (36 and 37) again.
PIA increases almost linearly with coverage over the range observed, although with slight 
diminishing marginal returns at upper levels (Table 1, Figure 3). Efficiency is flat across 
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lower levels of coverage but decreases slightly at higher levels. The more optimistic 
adherence pattern is able to increase PIA by roughly 3–9 percentage points across adherence 
levels, and reduce NNT by 6–8. Lower adherence operates in the opposite direction, but with 
a larger effect (on average 4–11 percentage points fewer infections averted relative to 
moderate adherence, increase in NNT always >12). The most optimistic scenario of all—
high (60%) coverage and high adherence—prevents just under half (47.2%) of new 
infections among ASMM.
In settings where background prevalence is lower than our main model, PIA declines slightly 
to moderately. Measured in absolute numbers of infections averted (NIA), effectiveness 
declines much more. NNT increases dramatically, to 85 and 75 (in moderate-prevalence 
settings with broad targeting and risk-based targeting, respectively), or 141 and 125 (for the 
same scenarios in lower-prevalence settings).
DISCUSSION
Our models suggest that PrEP has the potential to reduce HIV incidence significantly among 
adolescent sexual minority males (ASMM), with intervention efficiency for a generalized 
ASMM targeting strategy in higher-prevalence settings being less than twice that for highly 
targeted adult MSM interventions (14). Coverage strongly affects impact over the range 
examined, but has little effect on efficiency. Focusing on ASMM with the highest sexual risk 
behaviors decreases NNT, with the added challenge of ascertaining elements of sexual 
history beyond sexual identity. Targeting 16–18 year-olds has more efficiency than 13–18, 
and likely has higher feasibility and acceptability, especially in jurisdictions with an age of 
consent of 16 or with close-in-age exemptions that cover this age range (28, 29). A mean 6-
month delay in initiating PrEP after debut affects results marginally relative to immediate 
initiation, so a system of annual evaluations should represent a good balance of effectiveness 
and feasibility.
The impact and efficiency of our modeled interventions are directly dependent on current 
HIV burden, which varies across communities; higher burden makes PrEP much more 
efficient, and more effective in terms of absolute number of infections averted. Our main 
model was calibrated to 7% prevalence among 18-year-olds, an estimate derived from one 
Atlanta study and supported by additional studies of young adults in other large urban 
settings. In these calibrated simulations, the HIV prevalence seen among ASMM overall 
(13–18 years old) was 3.2%, with an incidence of 2.3/100 person-years among sexually-
initiated ASMM. The latter figure is lower than studies in Chicago and New York (9, 12); 
settings like these might experience higher efficiency than we estimate. In contrast, the many 
communities with ASMM incidence or prevalence lower than our model would see less 
impact and efficiency. Although we did not conduct a cost-effectiveness analysis, we can 
expect that cost-effectiveness will generally parallel efficiency. Our results provide a guide 
for jurisdictions to weigh their own estimates of ASMM HIV incidence or prevalence with 
their tolerance for levels of intervention impact and efficiency, in determining the value of 
ASMM PrEP scale-up, ideally within a cost-effectiveness analysis. Our results may also add 
further impetus for the FDA to evaluate PrEP indication for adolescents, a vital step in 
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achieving levels of coverage that could, like those modeled in this paper, make a significant 
impact on the epidemic.
The little data on potential PrEP adherence among ASMM comes from the ATN 113 trial, 
where it was lower than among adults, tapering off after 12 weeks when the study switched 
from monthly to quarterly visits (15). Our results suggest that lower adherence profiles may 
still yield considerable impact, so that if monthly visits are infeasible, ASMM PrEP may still 
be worth pursuing. However, these do not represent the full range over which adherence 
might vary in clinical practice, and may be high since the trial involved extensive 
counseling. More studies of adherence among ASMM will be needed, as will close 
monitoring in any ASMM demonstration trial. Increasing adherence among adolescent 
ASMM will help improve the efficiency and effectiveness of PrEP, and a large literature 
reveals the unique challenges of doing so in this population (30–32). Potential approaches 
include adapting strategies common to adherence efforts in general, including pill boxes, 
automated reminders, and case management. In addition, NIH is currently supporting the 
evaluation of several youth-specific PrEP adherence interventions, including a theoretically-
based mobile app and an adaptation of the LifeSteps intervention (33), both being evaluated 
through the Adolescent Trials Network (30–32). In the longer term, the adherence landscape 
may change dramatically if long-lasting injectable PrEP advances through trials to market 
(34).
Our study includes numerous limitations, including the fact that some parameters were 
based on relatively uncertain estimates. Two in particular (AI frequency within relationships 
and risk of HIV acquisition from older partners) were based on data that were either old or 
subject to strong desirability bias. Because our baseline model yielded low prevalence, we 
used these as uncertainty parameters. However, the mismatch between the observed HIV 
prevalence to which we calibrated (11) and that first predicted by our model may result from 
other forms of misspecification.
Our model assumed no risk compensation after PrEP initiation, since early reports from 
adult MSM found little evidence (13, 27). While preliminary ATN 113 results do not 
mention risk compensation directly, STI incidence declined over the study, suggesting little 
evidence of risk compensation (15). However, recent reports find risk compensation in adults 
(35–37), and any PrEP roll-out among adolescents would need to monitor closely for similar 
evidence.
Our model does not disaggregate risk or impact by race, despite large racial disparities in 
HIV among young MSM in the US. Targeting of PrEP within ASMM communities with the 
highest HIV burden may help reduce these large disparities; work on this extension is in 
progress. We also did not track ASMM beyond age 18, and thus miss multiple later-life 
effects of PrEP, meaning we cannot assess the impact of adolescent PrEP on the overall 
epidemic. Considering the full lifecourse could increase PrEP’s estimated impact and 
efficiency in two ways. First, it allows reduced HIV prevalence among men recently aged 
out of the ASMM population to reduce risk to ASMM through reductions in prevalence 
among partners. Second, adolescent engagement with PrEP may set a lifelong norm for 
MSM, leading to both higher lifelong retention and adherence. On the other hand, 
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considering the full lifecourse could reduce our estimates of impact and efficacy, since it 
might reveal that adolescent PrEP does not avert infections so much as postpone them. Such 
postponement, however, has the potential to avert additional secondary infections. 
Measuring the complete impact of PrEP for ASMM on HIV burden, whether for ASMM or 
for all MSM, thus requires a combined model for both communities that tracks ASMM 
across the lifecourse. We are currently conducting this work.
A growing body of evidence, including this model, indicates that over a range of coverage 
levels and with anticipated adherence and appropriate targeting, PrEP has the potential to 
substantially decrease HIV burden among adolescent sexual minority males, an underserved 
and at-risk population. Our work suggests optimal settings for PrEP outreach and delivery 
for ASMM. In higher-prevalence settings, an approach in which adolescent males are asked 
by a provider about their sexual identity on three occasions (once a year from ages 16–18) 
would provide information necessary for PrEP targeting that yields reasonable efficiency. 
One additional question about recent sexual activity could increase efficiency further, 
especially in lower-prevalence settings. In all cases, achieving reasonable uptake and 
retention will be key to intervention success. Making ASMM PrEP scalable will require 
strong buy-in from pediatricians or other providers, accompanied by strong training and 
support, as well as structural changes to expressly allow for minors to consent to PrEP. 
These will all likely be easier to achieve in higher-prevalence settings (28). More 
information on HIV burden among ASMM by jurisdiction, and more dissemination of that 
information, may increase PrEP willingness among both providers and ASMM (38, 39). All 
of these represent logistical challenges, although experiences from parallel endeavors (e.g. 
contraception for adolescents) will likely assist (40). Tackling these challenges could make a 
substantial impact in the large and often underappreciated HIV burden among US adolescent 
sexual minority males.
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ABBREVIATIONS
HIV human immunodeficiency virus
PrEP pre-exposure prophylaxis
ASMM adolescent sexual minority male
MSM men who have sex with men
NIA number of infections averted
PIA Percent of infections averted
NNT number needed to treat
CDC Centers for Disease Control and Prevention
STI sexually transmitted infections
AI anal intercourse
CAI condomless anal intercourse
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Figure 1. Intervention impact for nine base PrEP implementation scenarios
Boxplots show the median (center line), interquartile range (outer box) and 95% credible 
interval (whiskers) for each scenario. Scenario descriptions are found in Table 1. (a) Percent 
of infections averted (PIA); (b) number needed to treat (NNT).
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Figure 2. Time series of intervention impact, 16+ / 6 mos. base scenario
PrEP indications for this scenario are age 16–18 and having initiated anal intercourse; mean 
time until PrEP initiation is 6 months after indicated; coverage is 40%; adherence profile is 
drawn from the ATN 113 trial (see text). This corresponds to the first of the “base scenarios” 
listed in both Tables 1 and 2. Dark lines = means of 100 simulations from a given set of 
parameters; lighter areas = 95% credible interval across 100 simulations. (a) HIV prevalence 
among 18 year-old ASMM in the absence (blue) and presence (red) of PrEP over the 10 
years after rollout. Time scale on the x-axis reflects time relative to PrEP rollout; scenarios 
before this are identical and differ only through stochastic variation. (b) Cumulative 
percentage of infections averted (PIA) by the same PrEP indication scenario as in (a). The 
increase in PIA after the initial simulation is primarily due to the accumulation of indirect 
effects (see text).
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Figure 3. Intervention impact for sensitivity analyses
Boxplots show the median (center line), interquartile range (outer box) and 95% credible 
interval (whiskers) for each scenario. Scenario descriptions are found in Table 1. (a) Percent 
of infections averted (PIA); (b) number needed to treat (NNT). Note that the large difference 
in the median NNT for the C20+low scenario (50, shown here) and the mean (64, reported in 
Table 2) is due to individual simulation runs with very high NNT.
Goodreau et al. Page 15
J Adolesc Health. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Goodreau et al. Page 16
TA
B
LE
 1
N
am
es
 a
nd
 d
es
cr
ip
tio
ns
 o
f s
ce
na
rio
s m
od
el
ed
Sc
en
ar
io
 n
am
e
Ba
ck
gr
o
u
n
d 
A
SM
M
 H
IV
 
pr
ev
.
Pr
EP
 e
lig
ib
ili
ty
 c
ri
te
ri
a
Ti
m
in
g 
of
 P
rE
P 
in
iti
at
io
n
C
ov
er
a
ge
C
oh
or
t d
ist
ri
bu
tio
n 
by
 a
dh
er
en
ce
 
le
v
el
 (n
on
e, 
low
, 
m
ed
., 
hi
gh
)
H
ig
h 
pr
ev
.
 
ba
se
N
o 
Pr
EP
2.
9%
N
/A
N
/A
N
/A
N
/A
B
as
e 
sc
en
ar
io
s
16
+ 
/ 6
 m
os
.
A
ge
d 
16
–1
8 
an
d 
A
I e
x
pe
rie
nc
ed
6 
m
on
th
s a
fte
r 
el
ig
ib
ili
ty
40
%
20
.9
%
, 2
4.
4%
, 1
3.
1%
, 4
1.
6%
16
+ 
/ i
m
m
ed
.
at
 p
oi
nt
 o
f e
lig
ib
ili
ty
13
+ 
/ 6
 m
os
.
A
ge
d 
13
–1
8 
an
d 
A
I e
x
pe
rie
nc
ed
6 
m
on
th
s a
fte
r 
el
ig
ib
ili
ty
13
+ 
/ i
m
m
ed
.
at
 p
oi
nt
 o
f e
lig
ib
ili
ty
13
+ 
/ p
re
-A
I
2.
9%
A
ge
d 
13
–1
8
at
 p
oi
nt
 o
f s
ee
ki
ng
 fi
rs
t 
se
x
u
al
 p
ar
tn
er
sh
ip
16
+ 
/ C
A
I1
0
A
ge
d 
16
–1
8,
 ≥
 1
0 
ac
ts 
of
 C
A
I i
n 
th
e p
rio
r 6
 m
os
.
16
+ 
/ C
A
I5
A
ge
d 
16
–1
8,
 ≥
 5
 ac
ts 
of
 C
A
I i
n 
th
e p
rio
r 6
 m
os
.
at
 p
oi
nt
 o
f e
lig
ib
ili
ty
13
+ 
/ C
A
I1
0
A
ge
d 
13
–1
8,
 ≥
 1
0 
ac
ts 
of
 C
A
I i
n 
th
e 
pr
io
r 6
 m
os
.
13
+ 
/ C
A
I5
A
ge
d 
13
–1
8,
 ≥
 5
 ac
ts 
of
 C
A
I i
n 
th
e p
rio
r 6
 m
os
.
Se
ns
iti
v
ity
 a
na
ly
se
s
C2
0
20
%
20
.9
%
, 2
4.
4%
, 1
3.
1%
, 4
1.
6%
C3
0
30
%
C4
0a
2.
9%
A
ge
d 
16
–1
8 
an
d 
A
I e
x
pe
rie
nc
ed
6 
m
on
th
s a
fte
r 
el
ig
ib
ili
ty
40
%
C5
0
50
%
C6
0
60
%
C2
0 
+ 
H
i A
dh
20
%
4.
6%
, 1
8.
5%
, 1
6.
9%
, 6
0.
0%
C3
0 
+ 
H
i A
dh
30
%
C4
0 
+ 
H
i A
dh
2.
9%
A
ge
d 
16
–1
8 
an
d 
A
I e
x
pe
rie
nc
ed
6 
m
on
th
s a
fte
r 
el
ig
ib
ili
ty
40
%
C5
0 
+ 
H
i A
dh
50
%
C6
0 
+ 
H
i A
dh
60
%
C2
0 
+ 
Lo
w
 A
dh
20
%
46
.2
%
, 2
0.
5%
, 5
.1
%
, 2
8.
2%
C3
0 
+ 
Lo
w
 A
dh
2.
9%
A
ge
d 
16
–1
8 
an
d 
A
I e
x
pe
rie
nc
ed
6 
m
on
th
s a
fte
r 
el
ig
ib
ili
ty
30
%
J Adolesc Health. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Goodreau et al. Page 17
Sc
en
ar
io
 n
am
e
Ba
ck
gr
o
u
n
d 
A
SM
M
 H
IV
 
pr
ev
.
Pr
EP
 e
lig
ib
ili
ty
 c
ri
te
ri
a
Ti
m
in
g 
of
 P
rE
P 
in
iti
at
io
n
C
ov
er
a
ge
C
oh
or
t d
ist
ri
bu
tio
n 
by
 a
dh
er
en
ce
 
le
v
el
 (n
on
e, 
low
, 
m
ed
., 
hi
gh
)
C4
0 
+ 
Lo
w
 A
dh
40
%
C5
0 
+ 
Lo
w
 A
dh
50
%
C6
0 
+ 
Lo
w
 A
dh
60
%
M
ed
 p
re
v
 +
 n
o 
Pr
EP
N
/A
N
/A
40
%
20
.9
%
, 2
4.
4%
, 1
3.
1%
, 4
1.
6%
M
ed
 p
re
v
 / 
16
+ 
/ 6
 m
os
.
1.
5%
b
16
–1
8 
an
d 
A
I e
x
pe
rie
nc
ed
6 
m
on
th
s a
fte
r 
el
ig
ib
ili
ty
M
ed
 p
re
v
 / 
16
+ 
/ C
A
I1
0
16
–1
8,
 ≥
 1
0 
ac
ts 
of
 C
A
I i
n 
th
e p
rio
r 6
 m
on
th
s
at
 p
oi
nt
 o
f e
lig
ib
ili
ty
Lo
w
 p
re
v
 +
 n
o 
Pr
EP
N
/A
N
/A
Lo
w
 p
re
v
 / 
16
+ 
/ 6
 m
os
.
0.
9%
b
16
–1
8 
an
d 
A
I e
x
pe
rie
nc
ed
6 
m
on
th
s a
fte
r 
el
ig
ib
ili
ty
Lo
w
 p
re
v
 / 
16
+ 
/ C
A
I1
0
16
–1
8,
 >
10
 ac
ts 
of
 C
A
I i
n 
th
e p
rio
r 6
 m
on
th
s
at
 p
oi
nt
 o
f e
lig
ib
ili
ty
A
I =
 a
na
l i
nt
er
co
ur
se
 C
A
I =
 c
on
do
m
le
ss
 a
na
l i
nt
er
co
ur
se
a T
hi
s s
ce
na
rio
 m
at
ch
es
 th
e 
fir
st 
ba
se
 sc
en
ar
io
, b
u
t i
s r
ep
ea
te
d 
he
re
 fo
r e
as
ie
r c
om
pa
ris
on
 w
ith
 se
ns
iti
v
ity
 sc
en
ar
io
s
b M
ed
iu
m
 a
nd
 lo
w
 p
re
v
al
en
ce
 w
er
e 
se
le
ct
ed
 to
 b
e 
1/
2 
an
d 
1/
3 
of
 o
bs
er
ve
d 
pr
ev
al
en
ce
, r
es
pe
ct
iv
el
y.
 
10
0 
sim
ul
at
io
ns
 w
er
e 
co
nd
uc
te
d,
 a
nd
 th
os
e 
w
ith
in
 0
.0
5%
 o
f t
he
 ta
rg
et
 p
re
v
al
en
ce
 w
er
e 
in
cl
ud
ed
 in
 th
e 
fin
al
 a
na
ly
sis
.
J Adolesc Health. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Goodreau et al. Page 18
TA
B
LE
 2
M
od
el
 re
su
lts
M
ea
n 
(95
%
 C
re
d.
 In
t.)
Pr
ev
.
 
a
m
o
n
g 
18
 y
ea
r-
o
ld
 
A
SM
M
Pr
ev
.
 
a
m
o
n
g 
A
SM
M
In
c.
 (p
er
 10
0 p
y) 
am
on
g 
se
x
u
a
lly
 in
iti
at
ed
 A
SM
M
N
IA
PI
A
N
N
T
H
ig
h 
pr
ev
.
 
ba
se
N
o 
Pr
EP
7.
54
 (6
.15
–8
.79
)
3.
20
 (2
.66
–3
.74
)
2.
34
 (2
.12
–2
.54
)
B
as
e 
sc
en
ar
io
s
16
+ 
/ 6
 m
os
.
5.
46
 (4
.31
–6
.62
)
2.
43
 (1
.86
–2
.91
)
1.
67
 (1
.53
–1
.79
)
64
3.
3 
(52
0.8
–7
71
.9)
27
.8
 (2
2.3
–3
3.3
)
38
 (3
0–
45
)
16
+ 
/ i
m
m
ed
.
5.
38
 (4
.29
–6
.61
)
2.
40
 (1
.99
–2
.91
)
1.
62
 (1
.47
–1
.73
)
69
7.
4 
(56
9.9
–8
29
.1)
30
.1
 (2
4.6
–3
5.9
)
38
 (3
1–
44
)
13
+ 
/ 6
 m
os
.
4.
62
 (3
.38
–5
.64
)
1.
96
 (1
.60
–2
.26
)
1.
43
 (1
.33
–1
.54
)
86
8.
3 
(74
3.5
–9
64
.0)
37
.8
 (3
2.4
–4
1.4
)
40
 (3
6–
46
)
13
+ 
/ i
m
m
ed
.
4.
30
 (3
.25
–5
.45
)
1.
80
 (1
.47
–2
.11
)
1.
33
 (1
.23
–1
.42
)
96
4.
7 
(86
4.5
–1
05
8.3
)
42
.1
 (3
7.8
–4
6.0
)
41
 (3
7–
46
)
13
+ 
/ p
re
-A
I
4.
19
 (2
.99
–5
.15
)
1.
75
 (1
.39
–2
.06
)
1.
31
 (1
.22
–1
.41
)
98
1.
3 
(87
5.9
–1
07
1.9
)
42
.8
 (3
8.0
–4
6.8
)
42
 (3
8–
46
)
16
+ 
/ C
A
I1
0
5.
40
 (4
.10
–6
.83
)
2.
41
 (1
.89
–3
.03
)
1.
67
 (1
.54
–1
.82
)
65
0.
1 
(48
2.8
–7
65
.7)
28
.1
 (2
1.0
–3
3.2
)
35
 (2
9–
46
)
16
+ 
/ C
A
I5
5.
36
 (4
.32
–6
.52
)
2.
40
 (1
.99
–2
.81
)
1.
65
 (1
.52
–1
.77
)
66
5.
2 
(53
3.9
–7
90
.9)
28
.8
 (2
3.0
–3
3.8
)
36
 (2
9–
43
)
13
+ 
/ C
A
I1
0
4.
37
 (3
.28
–5
.52
)
1.
85
 (1
.38
–2
.28
)
1.
39
 (1
.28
–1
.50
)
90
5.
3 
(79
2.1
–1
00
1.6
)
39
.4
 (3
4.4
–4
3.6
)
36
 (3
2–
40
)
13
+ 
/ C
A
I5
4.
35
 (3
.47
–5
.35
)
1.
83
 (1
.48
–2
.19
)
1.
37
 (1
.24
–1
.48
)
92
8.
5 
(81
6.8
–1
04
1.2
)
40
.4
 (3
5.6
–4
4.9
)
37
 (3
2–
42
)
Se
ns
iti
v
ity
 a
na
ly
se
s
C2
0
6.
44
 (4
.88
–7
.81
)
2.
79
 (2
.24
–3
.30
)
1.
99
 (1
.83
–2
.12
)
34
2.
1 
(20
1.7
–4
69
.0)
14
.7
 (8
.6–
20
.3)
38
 (2
5–
57
)
C3
0
5.
80
 (4
.41
–7
.12
)
2.
54
 (1
.98
–3
.10
)
1.
81
 (1
.65
–1
.96
)
50
9.
9 
(35
3.9
–6
70
.6)
22
.0
 (1
5.2
–2
8.8
)
37
 (2
7–
51
)
C4
0*
5.
46
 (4
.31
–6
.62
)
2.
43
 (1
.86
–2
.91
)
1.
67
 (1
.53
–1
.79
)
64
3.
3 
(52
0.8
–7
71
.9)
27
.8
 (2
2.3
–3
3.3
)
38
 (3
0–
45
)
C5
0
5.
14
 (3
.80
–6
.28
)
2.
28
 (1
.80
–2
.68
)
1.
55
 (1
.42
–1
.69
)
76
0.
3 
(60
4.6
–8
91
.5)
32
.9
 (2
6.2
–3
8.6
)
39
 (3
3–
48
)
C6
0
4.
57
 (3
.40
–6
.14
)
2.
08
 (1
.68
–2
.50
)
1.
41
 (1
.26
–1
.54
)
89
4.
1 
(76
1.3
–1
04
1.1
)
38
.8
 (3
2.8
–4
5.2
)
39
 (3
4–
46
)
C2
0 
+ 
H
i A
dh
6.
18
 (4
.61
–7
.65
)
2.
71
 (2
.17
–3
.19
)
1.
90
 (1
.73
–2
.07
)
41
8.
2 
(22
5.8
–5
81
.9)
18
.0
 (9
.8–
25
.0)
30
 (2
1–
49
)
C3
0 
+ 
H
i A
dh
5.
49
 (4
.07
–6
.82
)
2.
47
 (1
.97
–3
.02
)
1.
69
 (1
.55
–1
.87
)
62
5.
8 
(44
4.5
–7
59
.4)
27
.0
 (1
9.3
–3
2.8
)
29
 (2
4–
40
)
C4
0 
+ 
H
i A
dh
5.
02
 (3
.66
–6
.19
)
2.
27
 (1
.83
–2
.78
)
1.
52
 (1
.39
–1
.63
)
78
5.
8 
(67
3.8
–9
02
.8)
34
.0
 (2
9.1
–3
9.2
)
31
 (2
6–
35
)
C5
0 
+ 
H
i A
dh
4.
50
 (3
.33
–5
.55
)
2.
08
 (1
.71
–2
.45
)
1.
35
 (1
.21
–1
.45
)
95
2.
3 
(84
7.3
–1
08
6.7
)
41
.4
 (3
6.7
–4
6.9
)
31
 (2
7–
35
)
C6
0 
+ 
H
i A
dh
4.
05
 (3
.10
–5
.04
)
1.
92
 (1
.60
–2
.33
)
1.
21
 (1
.10
–1
.33
)
10
83
.6
 (9
50
.9–
11
92
.2)
47
.2
 (4
1.2
–5
1.8
)
33
 (2
9–
37
)
C2
0 
+ 
Lo
w
 A
dh
6.
74
 (5
.36
–8
.40
)
2.
93
 (2
.21
–3
.47
)
2.
09
 (1
.94
–2
.25
)
24
2.
5 
(74
.8–
38
3.7
)
10
.4
 (3
.2–
16
.5)
64
 (3
0–
14
4)
C3
0 
+ 
Lo
w
 A
dh
6.
30
 (4
.89
–7
.73
)
2.
72
 (2
.18
–3
.26
)
1.
95
 (1
.79
–2
.10
)
37
2.
5 
(22
2.8
–5
24
.9)
16
.0
 (9
.6–
22
.8)
51
 (3
4–
80
)
C4
0 
+ 
Lo
w
 A
dh
5.
90
 (4
.56
–7
.18
)
2.
58
 (2
.10
–2
.93
)
1.
84
 (1
.70
–1
.96
)
47
5.
4 
(34
8.0
–6
13
.0)
20
.5
 (1
5.1
–2
6.4
)
51
 (3
9–
67
)
C5
0 
+ 
Lo
w
 A
dh
5.
77
 (4
.36
–6
.77
)
2.
52
 (2
.00
–3
.08
)
1.
74
 (1
.60
–1
.88
)
57
2.
4 
(43
3.9
–6
92
.0)
24
.7
 (1
8.9
–2
9.7
)
53
 (4
2–
68
)
C6
0 
+ 
Lo
w
 A
dh
5.
45
 (4
.06
–6
.88
)
2.
39
 (1
.88
–2
.90
)
1.
67
 (1
.53
–1
.80
)
64
5.
5 
(51
0.3
–7
64
.5)
27
.9
 (2
2.0
–3
3.0
)
55
 (4
5–
69
)
J Adolesc Health. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Goodreau et al. Page 19
M
ea
n 
(95
%
 C
re
d.
 In
t.)
Pr
ev
.
 
a
m
o
n
g 
18
 y
ea
r-
o
ld
 
A
SM
M
Pr
ev
.
 
a
m
o
n
g 
A
SM
M
In
c.
 (p
er
 10
0 p
y) 
am
on
g 
se
x
u
a
lly
 in
iti
at
ed
 A
SM
M
N
IA
PI
A
N
N
T
M
ed
 p
re
v
 +
 N
o 
Pr
EP
3.
43
 (2
.63
–4
.11
)
1.
43
 (1
.18
–1
.67
)
1.
01
 (0
.95
–1
.06
)
M
ed
 p
re
v
 +
 s
ce
na
rio
 1
3.
44
 (2
.38
–4
.39
)
1.
44
 (1
.17
–1
.76
)
1.
02
 (0
.93
–1
.09
)
28
3.
0 
(22
2.6
–3
43
.2)
21
.9
 (1
7.0
–2
6.8
)
85
 (6
0–
90
)
M
ed
 p
re
v
 +
 s
ce
na
rio
 6
2.
65
 (1
.88
–3
.52
)
1.
04
 (0
.81
–1
.26
)
0.
79
 (0
.71
–0
.86
)
27
3.
1 
(19
2.7
–3
36
.9)
21
.1
 (1
4.9
–2
6.2
)
75
 (4
7–
80
)
Lo
w
 p
re
v
 +
 N
o 
Pr
EP
2.
10
 (1
.48
–2
.80
)
0.
85
 (0
.64
–1
.08
)
0.
62
 (0
.56
–0
.67
)
Lo
w
 p
re
v
 +
 s
ce
na
rio
 1
2.
14
 (1
.57
–2
.76
)
0.
89
 (0
.57
–0
.98
)
0.
63
 (0
.58
–0
.67
)
17
6.
0 
(11
8.8
–2
29
.8)
22
.2
 (1
5.0
–3
9.0
)
14
1(1
03
–1
97
)
Lo
w
 p
re
v
 +
 s
ce
na
rio
 6
7.
54
 (6
.15
–8
.79
)
3.
20
 (2
.66
–3
.74
)
2.
34
 (2
.12
–2
.54
)
16
2.
6 
(11
9.8
–2
05
.2)
20
.5
 (1
5.1
–2
6.1
)
12
5 
(95
–1
64
)
A
SM
M
 =
 a
do
le
sc
en
t s
ex
u
al
 m
in
or
ity
 m
al
es
Cr
ed
. I
nt
 =
 c
re
di
bl
e 
in
te
rv
al
 fr
om
 th
e 
ra
ng
e 
of
 si
m
ul
at
io
ns
Pr
ev
.
 
=
 p
re
v
al
en
ce
 (m
ea
su
red
 10
 ye
ars
 af
ter
 Pr
EP
 ro
llo
ut)
In
c.
 =
 in
ci
de
nc
e 
(pe
r 1
00
 pe
rso
n y
ea
rs,
 m
ea
su
red
 in
 10
th 
ye
ar 
aft
er 
Pr
EP
 ro
llo
ut)
N
IA
 =
 n
um
be
r o
f i
nf
ec
tio
ns
 av
er
te
d,
 p
er
 1
00
k 
ye
ar
s o
f p
er
so
n-
tim
e 
at
 ri
sk
 (m
ea
su
red
 ac
ros
s 1
0 y
ea
rs 
fol
low
in
g 
Pr
EP
 ro
llo
ut
) P
IA
 = 
pe
rce
nt 
of 
inf
ec
tio
ns
 av
er
te
d 
(m
ea
su
red
 ac
ros
s 1
0 y
ea
rs 
fol
low
in
g 
Pr
EP
 
ro
llo
ut
)
N
N
T 
= 
nu
m
be
r n
ee
de
d 
to
 tr
ea
t =
 p
er
so
n-
ye
ar
s o
n 
Pr
EP
 p
er
 c
as
e 
av
er
te
d 
(m
ea
su
red
 ac
ros
s 1
0 y
ea
rs 
fol
low
in
g 
Pr
EP
 ro
llo
ut
)
*
Th
is 
sc
en
ar
io
 m
at
ch
es
 th
e 
fir
st 
ba
se
 sc
en
ar
io
, b
u
t i
s r
ep
ea
te
d 
he
re
 fo
r e
as
ie
r c
om
pa
ris
on
 w
ith
 se
ns
iti
v
ity
 sc
en
ar
io
s
J Adolesc Health. Author manuscript; available in PMC 2019 March 01.
